Equity Analysis /
United States of America

Microsoft Corp: US : ADMA Biologics, Inc. - ADMA | Pre-Announces Better-Than-Expected 4Q20 Revenue; Dialing In On 2024 Target

    Lucas Lee
    Lucas Lee

    Sr. Res. Assoc.

    19 January 2021
    Published byCGS-CIMB

    ADMA has begun to build on the top-line momentum of the past year, pre-announcing year-end results that easily topped external estimates. More importantly, the company signaled continued sequential and y/y growth trends over the course of the year as management progresses the story toward its ultim